Parkinson's disease: prospects for improved drug therapy
Identifieur interne : 001F45 ( Main/Exploration ); précédent : 001F44; suivant : 001F46Parkinson's disease: prospects for improved drug therapy
Auteurs : Jim J. Hagan [Royaume-Uni] ; Derek N. Middlemiss [Royaume-Uni] ; Paul C. Sharpe [Royaume-Uni] ; George H. Poste [Royaume-Uni]Source :
- Trends in Pharmacological Sciences [ 0165-6147 ] ; 1997.
Abstract
l-Dopa has long been the mainstay of therapy for Parkinson's disease but its long-term shortcomings, principally uncoordinated, spasmodic or irregular movements (dyskinesias) and fluctuating control of motor symptoms (on/off fluctuations), are well documented. The postulated neuroprotective properties of l-deprenyl, often used as an adjunct to l-dopa, are under scrutiny and doubts have also been raised regarding its safety. Alternative therapeutic approaches are clearly needed. In this review, Jim Hagan, Derek Middlemiss, Paul Sharpe and George Poste outline some new approaches to treatment, with an emphasis on novel, selective dopamine receptor agonists. In addition, Parkinson's disease is commonly thought to be caused by the neurotoxic effects of an unidentified agent but recent data indicate a greater genetic component than previously recognized. Developments in the genetics of Parkinson's disease may provide the key to the next generation of therapeutics.
Url:
DOI: 10.1016/S0165-6147(97)90612-X
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Parkinson's disease: prospects for improved drug therapy</title><author><name sortKey="Hagan, Jim J" sort="Hagan, Jim J" uniqKey="Hagan J" first="Jim J." last="Hagan">Jim J. Hagan</name></author><author><name sortKey="Middlemiss, Derek N" sort="Middlemiss, Derek N" uniqKey="Middlemiss D" first="Derek N." last="Middlemiss">Derek N. Middlemiss</name></author><author><name sortKey="Sharpe, Paul C" sort="Sharpe, Paul C" uniqKey="Sharpe P" first="Paul C." last="Sharpe">Paul C. Sharpe</name></author><author><name sortKey="Poste, George H" sort="Poste, George H" uniqKey="Poste G" first="George H." last="Poste">George H. Poste</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7644CBCB7185FE918503CE41685C2015B76E9CC8</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0165-6147(97)90612-X</idno><idno type="url">https://api.istex.fr/document/7644CBCB7185FE918503CE41685C2015B76E9CC8/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002226</idno><idno type="wicri:Area/Main/Curation">001F13</idno><idno type="wicri:Area/Main/Exploration">001F45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Parkinson's disease: prospects for improved drug therapy</title><author><name sortKey="Hagan, Jim J" sort="Hagan, Jim J" uniqKey="Hagan J" first="Jim J." last="Hagan">Jim J. Hagan</name><affiliation wicri:level="1"><country>Royaume-Uni</country><wicri:regionArea>Research and Development, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow</wicri:regionArea><wicri:noRegion>Harlow</wicri:noRegion></affiliation></author><author><name sortKey="Middlemiss, Derek N" sort="Middlemiss, Derek N" uniqKey="Middlemiss D" first="Derek N." last="Middlemiss">Derek N. Middlemiss</name><affiliation wicri:level="1"><country>Royaume-Uni</country><wicri:regionArea>Research and Development, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow</wicri:regionArea><wicri:noRegion>Harlow</wicri:noRegion></affiliation></author><author><name sortKey="Sharpe, Paul C" sort="Sharpe, Paul C" uniqKey="Sharpe P" first="Paul C." last="Sharpe">Paul C. Sharpe</name><affiliation wicri:level="1"><country>Royaume-Uni</country><wicri:regionArea>Research and Development, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow</wicri:regionArea><wicri:noRegion>Harlow</wicri:noRegion></affiliation></author><author><name sortKey="Poste, George H" sort="Poste, George H" uniqKey="Poste G" first="George H." last="Poste">George H. Poste</name><affiliation wicri:level="1"><country>Royaume-Uni</country><wicri:regionArea>Research and Development, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow</wicri:regionArea><wicri:noRegion>Harlow</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Trends in Pharmacological Sciences</title><title level="j" type="abbrev">TIPS</title><idno type="ISSN">0165-6147</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="156">156</biblScope><biblScope unit="page" to="163">163</biblScope></imprint><idno type="ISSN">0165-6147</idno></series><idno type="istex">7644CBCB7185FE918503CE41685C2015B76E9CC8</idno><idno type="DOI">10.1016/S0165-6147(97)90612-X</idno><idno type="PII">S0165-6147(97)90612-X</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0165-6147</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">l-Dopa has long been the mainstay of therapy for Parkinson's disease but its long-term shortcomings, principally uncoordinated, spasmodic or irregular movements (dyskinesias) and fluctuating control of motor symptoms (on/off fluctuations), are well documented. The postulated neuroprotective properties of l-deprenyl, often used as an adjunct to l-dopa, are under scrutiny and doubts have also been raised regarding its safety. Alternative therapeutic approaches are clearly needed. In this review, Jim Hagan, Derek Middlemiss, Paul Sharpe and George Poste outline some new approaches to treatment, with an emphasis on novel, selective dopamine receptor agonists. In addition, Parkinson's disease is commonly thought to be caused by the neurotoxic effects of an unidentified agent but recent data indicate a greater genetic component than previously recognized. Developments in the genetics of Parkinson's disease may provide the key to the next generation of therapeutics.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Hagan, Jim J" sort="Hagan, Jim J" uniqKey="Hagan J" first="Jim J." last="Hagan">Jim J. Hagan</name></noRegion><name sortKey="Middlemiss, Derek N" sort="Middlemiss, Derek N" uniqKey="Middlemiss D" first="Derek N." last="Middlemiss">Derek N. Middlemiss</name><name sortKey="Poste, George H" sort="Poste, George H" uniqKey="Poste G" first="George H." last="Poste">George H. Poste</name><name sortKey="Sharpe, Paul C" sort="Sharpe, Paul C" uniqKey="Sharpe P" first="Paul C." last="Sharpe">Paul C. Sharpe</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7644CBCB7185FE918503CE41685C2015B76E9CC8
|texte= Parkinson's disease: prospects for improved drug therapy
}}
| This area was generated with Dilib version V0.6.23. |  |